New cancer clinical trial: NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Published on: October 01, 2018 at 09:30PM

• Tweet
• Share
• Share
• Share
• Share